1. Home
  2. TNXP vs CXDO Comparison

TNXP vs CXDO Comparison

Compare TNXP & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • CXDO
  • Stock Information
  • Founded
  • TNXP 2007
  • CXDO 1995
  • Country
  • TNXP United States
  • CXDO United States
  • Employees
  • TNXP N/A
  • CXDO N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • CXDO Telecommunications Equipment
  • Sector
  • TNXP Health Care
  • CXDO Telecommunications
  • Exchange
  • TNXP Nasdaq
  • CXDO Nasdaq
  • Market Cap
  • TNXP 173.9M
  • CXDO 196.8M
  • IPO Year
  • TNXP N/A
  • CXDO 1998
  • Fundamental
  • Price
  • TNXP $18.49
  • CXDO $6.49
  • Analyst Decision
  • TNXP Buy
  • CXDO Strong Buy
  • Analyst Count
  • TNXP 1
  • CXDO 4
  • Target Price
  • TNXP $70.00
  • CXDO $9.00
  • AVG Volume (30 Days)
  • TNXP 851.8K
  • CXDO 80.4K
  • Earning Date
  • TNXP 11-07-2025
  • CXDO 11-04-2025
  • Dividend Yield
  • TNXP N/A
  • CXDO N/A
  • EPS Growth
  • TNXP N/A
  • CXDO 13.31
  • EPS
  • TNXP N/A
  • CXDO 0.11
  • Revenue
  • TNXP $9,831,000.00
  • CXDO $64,476,000.00
  • Revenue This Year
  • TNXP $14.79
  • CXDO $13.46
  • Revenue Next Year
  • TNXP $933.49
  • CXDO $11.27
  • P/E Ratio
  • TNXP N/A
  • CXDO $58.62
  • Revenue Growth
  • TNXP N/A
  • CXDO 13.10
  • 52 Week Low
  • TNXP $6.76
  • CXDO $3.75
  • 52 Week High
  • TNXP $130.00
  • CXDO $7.34
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 31.62
  • CXDO 55.44
  • Support Level
  • TNXP $18.53
  • CXDO $6.18
  • Resistance Level
  • TNXP $20.58
  • CXDO $6.52
  • Average True Range (ATR)
  • TNXP 1.09
  • CXDO 0.21
  • MACD
  • TNXP 0.41
  • CXDO 0.04
  • Stochastic Oscillator
  • TNXP 7.04
  • CXDO 96.97

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About CXDO Crexendo Inc.

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.

Share on Social Networks: